Muscle-invasive Bladder Cancer
📧 Sign up to get email alerts when something new happens for Muscle-invasive Bladder Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) [Phase 2]
SWOG's Phase 2 trial evaluating adding avelumab to gemcitabine and carboplatin before surgery in cisplatin-ineligible muscle-invasive urinar…
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) [NA]
A clinical trial from University of Virginia is investigating pre-habilitation with mindfulness and exercise for bladder cancer patients und…
-
CLINICAL_TRIALS trial_result · 2024-12-05Clinical Trial Update: Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach [Phase 2]
Phase 2 trial evaluating durvalumab plus tremelimumab with concurrent radiotherapy for localized muscle-invasive bladder cancer treated with…
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30) [NA]
This clinical trial update covers GETUG-AFU 30, a study on adjuvant radiotherapy for patients with pathological high-risk muscle-invasive bl…
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients [Phase 1, Phase 2]
Phase 1/2 trial evaluating RC48 (disitamab vedotin) in combination with toripalimab as neoadjuvant therapy for cisplatin-ineligible muscle-i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-12-04Clinical Trial Update: Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer [Phase 2]
Phase 2 clinical trial evaluating cabozantinib in combination with atezolizumab for muscle-invasive bladder cancer; the study is currently a…
-
CLINICAL_TRIALS research · 2024-12-02Clinical Trial Update: Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM) [NA]
A clinical trial update for HIRACUM evaluating hypofractionated IMRT with concurrent chemotherapy in muscle-invasive bladder cancer, current…
-
CLINICAL_TRIALS research · 2024-11-25Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) [Phase 3]
This clinical trial update describes the ongoing Phase 3 study MK-3475-992 (KEYNOTE-992) evaluating pembrolizumab plus chemoradiotherapy ver…
-
CLINICAL_TRIALS research · 2024-11-22Clinical Trial Update: Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging [NA]
Completed clinical trial evaluating the impact of positron emission tomography (PET) imaging on staging for muscle-invasive bladder cancer.
-
CLINICAL_TRIALS research · 2024-10-04Clinical Trial Update: Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer [Phase 2]
Phase 2 trial evaluating cisplatin, nab-paclitaxel, and nivolumab with radiotherapy after resection in non-metastatic muscle-invasive bladde…
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients [Phase 2]
Phase 2 clinical trial evaluating sasanlimab as maintenance therapy after neoadjuvant treatment in molecularly categorized muscle-invasive b…
-
CLINICAL_TRIALS withdrawal · 2024-09-25Clinical Trial Update: Clinical Performance Evaluation of the C2i Test
The clinical trial NCT05860543 evaluating the C2i Test for muscle-invasive bladder cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer [Phase 1]
Phase 1 trial assessing the safety and tolerability of TAR-200 in combination with nivolumab in muscle-invasive bladder cancer; the study ha…
-
CLINICAL_TRIALS research · 2024-07-30Clinical Trial Update: Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer [Phase 2]
Phase 2 trial exploring bladder-preserving therapy with sacituzumab govitecan plus zimberelimab for muscle-invasive bladder cancer; the stud…
-
CLINICAL_TRIALS research · 2024-07-12Clinical Trial Update: Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer [Phase 2]
An update on a Phase 2 trial evaluating risk-stratified bladder-sparing modalities for muscle-invasive bladder cancer, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing [Phase 2]
Phase 2 trial evaluating the combination of gemcitabine, cisplatin, and nivolumab in muscle-invasive bladder cancer with selective bladder-s…
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer [Phase 3]
Phase 3 trial comparing Nivolumab plus Bempegaldesleukin versus Nivolumab alone and standard of care in cisplatin-ineligible muscle-invasive…
-
CLINICAL_TRIALS research · 2024-05-20Clinical Trial Update: mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer [NA]
The document discusses a clinical trial comparing mpMRI to diagnostic TURBT for suspected muscle-invasive bladder cancer and notes that recr…
-
CLINICAL_TRIALS trial_result · 2024-04-04Clinical Trial Update: AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer [Phase 2]
Phase 2 trial evaluating AGEN1884 plus AGEN2034 with cisplatin-gemcitabine for muscle-invasive bladder cancer was terminated, with results p…
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer [Phase 2]
Phase 2 trial update evaluating RC48-ADC combined with JS001 as perioperative treatment for muscle-invasive bladder cancer.
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer [Phase 2]
Phase 2 trial evaluating RC48-ADC in combination with AK104 for perioperative treatment of muscle-invasive bladder cancer.
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC [Phase 2]
Phase 2 trial evaluating RC48 plus toripalimab and radiotherapy for bladder-sparing treatment in muscle invasive bladder cancer with HER2 ex…
-
CLINICAL_TRIALS trial_result · 2023-08-24Clinical Trial Update: Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer [Phase 2]
Phase 2 trial update of cadonilimab plus nab-paclitaxel for recurrent or metastatic muscle-invasive bladder cancer (bladder cancer).
-
CLINICAL_TRIALS trial_result · 2023-07-18Clinical Trial Update: Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma [Phase 2]
Phase 2 trial update on neoadjuvant pembrolizumab for muscle-invasive urothelial bladder carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab [Phase 2]
A Phase 2 neoadjuvant trial assessing pembrolizumab monotherapy in muscle-invasive bladder cancer to study mechanisms of action.